
**Louisiana Department of Health
Medicaid Pharmaceutical and Therapeutics Committee
628 North Fourth Street
Baton Rouge, LA 70802
Bienville Building, Room #118
May 6, 2026
9:00 AM**

- I. Call to Order Jill Comeau
Pharmacist, ULM
- II. Introduction Seth Gold
Executive Medicaid Director, LDH
Sharon Yeske
Pharmacy Director, LDH
- III. Parliamentary Business Jill Comeau
- A. Introduction of Members/Roll Call
- B. Attendance
- C. Approval of Meeting Minutes November 5, 2025
- IV. Ethics Kimberly Boudreaux
Deputy General Counsel, LDH
- V. Reports Sue Fontenot
Pharmacist, LDH
- VI. New Business Renesha Yarbrough
Clinical Account Manager, Prime Therapeutics
- A. Explanation of TOP\$, Monographs and Cost Sheets
- B. Therapeutic Class Reviews /Public Testimony
1. Acne Agents, Topical
 2. Analgesics, Narcotics Long
 3. Analgesics, Narcotics Short
 4. Androgenic Agents
 5. Angiotensin Modulator Combinations
 6. Angiotensin Modulators
 7. Antibiotics, GI
 8. Antibiotics, Inhaled
 9. Antibiotics, Topical
 10. Antibiotics, Vaginal
 11. Anticoagulants
 12. Antiemetic/Antivertigo Agents
 13. Antifungals, Oral

14. Antifungals, Topical
15. Antihistamines, First Generation
16. Antimigraine Agents, Other
17. Antimigraine Agents, Triptans
18. Antiparasitics, Topical
19. Antivirals, General
20. Antivirals, Oral
21. Antivirals, Topical
22. Beta-Blockers
23. Bladder Relaxant Preparations
24. Bone Resorption Suppression and Related Agents
25. BPH Treatments
26. Calcium Channel Blockers
27. Cephalosporins and Related Antibiotics
28. Cystic Fibrosis, Oral
29. Fluoroquinolones, Oral
30. GI Motility, Chronic
31. Glucagon Agents
32. Growth Factors
33. Growth Hormone
34. H. Pylori Treatment
35. HAE Treatments
36. Hepatitis B Agents
37. Hepatitis C Agents
38. Hepatitis C Agents Treatment Course
39. HIV/AIDS
40. Hypoglycemics, Alpha-Glucosidase Inhibitors
41. Hypoglycemics, Incretin Mimetics/Enhancers
42. Hypoglycemics, Insulin and Related Agents
43. Hypoglycemics, Meglitinides
44. Hypoglycemics, Metformins
45. Hypoglycemics, SGLT2
46. Hypoglycemics, Sulfonylureas
47. Hypoglycemics, TZD
48. Immunosuppressives, Oral
49. Lincosamides/Oxazolidinones/Streptogramins
50. Lipotropics, Other
51. Lipotropics, Statins
52. Macrolides/Ketolides
53. Multiple Sclerosis Agents
54. Multivitamins
55. Nitrofurans Derivatives
56. Opiate Dependence Treatments
57. PAH Agents, Oral and Inhaled
58. Pancreatic Enzymes
59. Pediatric Vitamin Preparations

- 60. Penicillins
- 61. Phosphate Binders
- 62. Pituitary Suppressive Agents, LHRH
- 63. Platelet Aggregation Inhibitor
- 64. Potassium Binders
- 65. Prenatal Vitamins
- 66. Proton Pump Inhibitors
- 67. Sinus Node Inhibitors
- 68. Skeletal Muscle Relaxants
- 69. Tetracyclines
- 70. Ulcerative Colitis Agents
- 71. Uterine Disorder Treatments
- 72. Vasodilators, Coronary

VII. Single Drug Reviews

Renisha Yarbrough

- 73. Anticonvulsants – Subvenite Suspension (Oral)
- 74. Antihypertensives, Sympatholytics – Javadin Solution (Oral)
- 75. Cytokine and Cam Antagonists – Starjemza Syringe (Subcutane.)
- 76. Cytokine and Cam Antagonists – Starjemza Vial (Subcutane.)
- 77. Cytokine and Cam Antagonists – Starjemza Vial (Intravenous)
- 78. Cytokine and Cam Antagonists – Otezla XR Initiation Pak (Oral)
- 79. Cytokine and Cam Antagonists – Otezla XR Tablet (Oral)
- 80. Idiopathic Pulmonary Fibrosis – Jascayd Tablet (Oral)
- 81. Immunomodulators, Atopic Dermatitis – Zoryve 0.05% Cream (Topical)
- 82. NSAIDS - Vyscoxa Suspension (Oral)
- 83. NSAIDS – Coxanto (Oral)
- 84. Oncology, Oral Breast - Inluriyo Tablet (Oral)
- 85. Oncology, Oral Other – Koselugo Cap Sprink (Oral)
- 86. Spinal Muscular Atrophy – Itvisma Vial (Intrathecal)
- 87. Steroids, Topical High – Halog Solution (Topical)
- 88. Thrombopoiesis Stimulating Proteins – Doptelet Sprinkle (Oral)

VIII. Next Steps

- A. Proposed Therapeutic Classes to be reviewed at Next Meeting

IX. Proposed Next Meeting Dates

- A. Wednesday, November 4, 2026 or Friday, November 6, 2026

X. Public Testimony